コンポーネント:
治療オプション:
Militian Inessa Mesropovna 、薬局による医学的評価、 最終更新日:29.03.2022
アテンション! そのこのページの情報は医療専門家のみを対象としています! その情報が収集したオープン源を含めることが可能である重大な誤差! 注意して、このページ上のすべての情報を再確認してください!
同じ成分を持つトップ20の薬:
Posology
For oral use.
For the different dosage regimens suitable strengths are available.
The dose of Teracin(ANTIHYPERTENSIVES) should be adjusted according to the patient's response.
The following is a guide to administration:
Initial dose
The lowest single dose of 1 mg before bedtime for all patients, which should not be exceeded. Strict compliance with this recommendation should be observed to minimise potential acute first-dose hypotensive episodes.
Subsequent doses
Treatment of mild to moderate hypertension:
The single daily dosage may be increased by approximately doubling the dosage at weekly intervals to achieve the desired blood pressure response.
The maintenance dose needs to be adjusted to the patient's response. 2 mg/day may be sufficient with increases up to 10 mg if necessary (clinical studies support the use of 2 - 10 mg as maintenance dose).
The maximum dose is 20 mg of Teracin(ANTIHYPERTENSIVES) per day and should not be exceeded.
Use with thiazide diuretics and other antihypertensive agents in the treatment of hypertension:
When adding a thiazide diuretic or another antihypertensive agent to a patient's regimen the dose of Teracin(ANTIHYPERTENSIVES) should be reduced or discontinued and retitration carried out if necessary. Caution should be observed when Teracin(ANTIHYPERTENSIVES) is administered with thiazides or other antihypertensive agents as hypotension may develop.
Treatment of Benign Prostatic Hyperplasia:
The dose may be increased by approximately doubling at weekly or bi-weekly intervals to achieve the desired reduction in symptoms. The maintenance dose is usually 5 to 10 mg once daily. Improvements in symptoms have been detected as early as two weeks after starting treatment with Teracin(ANTIHYPERTENSIVES).
At present there are insufficient data to suggest additional symptomatic relief with doses above 10 mg once daily.
Treatment should be initiated using the 1 mg tablets during seven days, 2 mg tablets during 14 days and 5 mg tablets during 7 days. Response to treatment must be reviewed at four weeks. Transient side effects may occur at each titration step. If any side effects persist, consideration should be given to reducing the dose.
Renal insufficiency
Pharmacokinetic studies indicate that patients with impaired renal function need no alteration in recommended dosage.
Children
Safety and efficacy in children has not been established.
Elderly
Pharmacokinetic studies in the elderly indicate that no major alteration in dosage recommendation is required. However, particular caution should be taken with the titration of the Teracin(ANTIHYPERTENSIVES) dose.
If administration is discontinued for more than several days, therapy should be re-instituted using the initial dosing regimen.
Use in patients with hepatic insufficiency:
The Teracin(ANTIHYPERTENSIVES) dose should be titrated with particular caution in patients with impaired liver function since Teracin(ANTIHYPERTENSIVES) undergoes extensive hepatic metabolism and is mainly excreted by the biliary tract. No clinical experience is available in patients with severe hepatic dysfunction.
Method of administration
The first tablet of a defined dose strength should be taken in the evening at bedtime. The following tablets of the same strength may be taken in the morning. The tablets should be taken with a sufficient amount of liquid (i.e. 1 glass of water).
Teracin(ANTIHYPERTENSIVES) therapy of hypertension is a long-term treatment, which should only be interrupted on medical advice. If it is necessary to stop Teracin(ANTIHYPERTENSIVES) therapy, the dose should be re-titrated starting with 1 mg Teracin(ANTIHYPERTENSIVES) at bedtime.
テラシン(抗ヒパーテンシブ)の投与が急性低血圧につながる場合;心血管サポートが最も重要です。. 血圧の回復と心拍数の正常化は、患者を仰 ⁇ 位に留めることによって達成できます。. この対策が不十分な場合は、まずショックをボリュームエキスパンダーで処理し、必要に応じてバソプレッサーを使用できます。. 腎機能を監視し、必要に応じて一般的な支援策を適用する必要があります。. 実験室データはテラシン(抗ヒパーテンシブ)がタンパク質に高度に結合していることを示しているため、透析は役に立たない可能性があります。.
吸収。
テラシン(抗体刺激薬)はよく吸収されます(80-100%)。. Teracin(ANTIHYPERTENSIVES)は最小限の「最初のパス」効果を持ち、Teracin(ANTIHYPERTENSIVES)のほぼ完全な用量が体系的に利用可能です。. ピーク血漿濃度は、空腹時の経口投与後約1〜2時間で到達します。. バイオアベイラビリティは、食物摂取による大きな影響を受けません。.
分布。
テラシン(抗ヒペルテンシブ)の約90〜94%が血漿タンパク質に結合しています。. タンパク質結合は、総活性物質濃度とは無関係です。.
生体内変化。
テラシンの主な代謝物(ANTIHYPERTENSIVES)は、脱メチル化と抱合によって引き起こされます。.
除去。
経口投与されたテラシン(ANTIHYPERTENSIVES)の約10%と20%は、変化のない活性物質としてそれぞれ尿と ⁇ 便中に排 ⁇ されます。. 投与された用量のテラシン(抗ヒペルテンシブ)の約40%が尿から、60%が ⁇ 便から排出されます。. 完全消失半減期は約8〜13時間です。.
直線性/非線形性。
テラシン(抗体刺激薬)AUCおよびCの経口投与後マックス。 推奨用量範囲(2-10 mg)を超える用量に比例して増加。.
However, we will provide data for each active ingredient